No Data
Jiangxi Fushine Pharmaceutical (300497.SZ) plans to establish subsidiaries in Shanghai and Singapore for the development and sale of Fushine microbiological protein consumer products.
Jiangxi Fushine Pharmaceutical (300497.SZ) announced that, in order to meet the needs of the company's global strategy and accelerate the expansion of microbial proteins...
Jiangxi Fushine Pharmaceutical (300497.SZ): Intends to establish a subsidiary.
Gelonghui November 7th | Jiangxi Fushine Pharmaceutical (300497.SZ) announced that, in order to meet the company's global strategy needs, accelerate the expansion of the microbial protein business market, the company plans to use its own funds to establish Fushine Microbial Protein Application Consumer Products Development and Sales subsidiaries in shanghai and Singapore, with registered capital not exceeding 10 million RMB and 3 million Singapore dollars respectively.
Fuxiang Pharmaceutical: Report for the third quarter of 2024
Jiangxi Fushine Pharmaceutical (300497.SZ) released its performance for the first three quarters, with a net loss of 62.075 million yuan.
Jiangxi Fushine Pharmaceutical (300497.SZ) released the report for the first three quarters of 2024, during which the company achieved revenue...
Jiangxi Fushine Pharmaceutical (300497.SZ): The net loss in the third quarter was 39.6157 million yuan.
GeLongHui October 23rd | Jiangxi Fushine Pharmaceutical (300497.SZ) released the third quarter report of 2024, with revenue of 0.294 billion yuan, a year-on-year decrease of 31.65%; net income attributable to shareholders of the listed company -39.6157 million yuan; net profit attributable to shareholders of the listed company excluding non-recurring gains and losses -44.7531 million yuan; basic earnings per share -0.07 yuan.
Fushine Pharmaceutical Unit Gets GMP Certificate
The Market Doesn't Like What It Sees From Jiangxi Fushine Pharmaceutical Co., Ltd.'s (SZSE:300497) Revenues YetNo Data
No Data
